Skip to content

Efficacy and Safety of Microwave Ablation in BosniakⅠ~ⅡF Cystic Renal Lesions

Efficacy and Safety of Microwave Ablation in BosniakⅠ~ⅡF Cystic Renal Lesions: Clinical Outcomes of a Randomised Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03068195
Enrollment
300
Registered
2017-03-01
Start date
2016-11-30
Completion date
2020-11-30
Last updated
2017-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Diseases,Cystic

Keywords

laparoscopy, microwave, ablation technique

Brief summary

The purpose of this study is to determine whether microwave ablation is more effective in the treatment of simple renal cysts than conventional laparoscopic decortication.

Detailed description

Background: Simple renal cysts are the most common renal masses, and occur in half of all patients older than 50 years.They are usually asymptomatic and benign, asymptomatic and discovered incidentally. However, over time, these simple cysts can enlarge, become symptomatic and develop complications, requiring intervention.They can be managed by a variety of surgical and percutaneous methods, including percutaneous aspiration (with or without injection of a sclerosing agent), endoscopic marsupialization or excision, open surgery and laparoscopic cyst excision.Percutaneous aspiration and sclerotherapy have been described as safe and effective methods of managing symptomatic simple renal cysts without the cost and morbidity associated with conventional surgery and laparoscopy.However, laparoscopic decortications and simple aspiration is associated with a high recurrence rate because the cyst wall epithelium is responsible for active liquid production. Purpose:To determine whether microwave ablation is more effective in the treatment of simple renal cysts than conventional laparoscopic decortication. Method:

Interventions

PROCEDUREmicrowave ablation

KY2000 microwave ablation system was used in the experimental group. A power output of 60 W for 1-3 min for 1-3 cycles to treat the renal cysts according to the cysts size and classification.Percutaneous microwave ablation will be performed under the guidance of ultrasound while the laparoscopic microwave ablation will be performed under direct vision

PROCEDURElaparoscopic decortication

conventional laparoscopic decortication will be performed to treat the renal cysts

Sponsors

RenJi Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* patients with sporadic, unilateral, newly diagnosed Bosniak Ⅰ, Ⅱ and ⅡF renal cyst * patients agreeable to participate in this long-term follow-up study * patients with normal contralateral renal function (differential renal function of \>40% as determined by radionuclide scintigraphy)

Exclusion criteria

* patients' aged \>80 years * patients not able to tolerate the microwave ablation procedure * patients with previous renal surgery or history of any inflammatory conditions of the operative kidney * patients with the renal cyst involving urinary collecting system * patients with other renal diseases,(including kidney stone, glomerular nephritis, etc.) which might affect the renal function of the operative kidney

Design outcomes

Primary

MeasureTime frame
local recurrence12 months postoperatively

Secondary

MeasureTime frame
postoperative complicationspostoperative,up to 30 days
operative timeduring operation
Hospital stay timetime from the date of admission until the date of discharge, up to 2 weeks
quality of life assessed by quality of life questionnairepostoperative,up to 6 months
change from baseline glomerular filtration rate (GFR) of the affected kidney, 12 months minus baselinebaseline and 12 months

Countries

China

Contacts

Primary ContactYonghui Chen
cyh1488@163.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026